American Greetings considers moving HQ
BROOKLYN, Ohio A popular greeting card maker is setting its sights on a new place to call home.
American Greetings on Friday said it is focusing on seven sites for the location of its 2,000-employee corporate headquarters. The headquarters currently is in Brooklyn, Ohio.
"We are an evolving company in a changing industry, and we must adapt our headquarters building –– whether it remains in Brooklyn or is relocated –– to most efficiently accommodate us today and in the future," said Brian McGrath, SVP human resources. "Competitive businesses that wish to remain successful must adjust and position themselves for the future, and that’s what American Greetings is doing by conducting an exhaustive examination of our workplace needs."
Subs keeps up with urban trend
NEW YORK — A new urban fashion accessory has hit the market.
Hatch Ventures recently introduced Subs, designed for consumers who wear baggy pants well below the waistline. Like traditional suspenders, Subs are designed to keep pants from falling down by cinching around the waist and are worn underneath a shirt. The wearer can control how long they want their pants to "sag," and prevent pants from falling any lower.
Subs carry a suggested retail price of $34.95 and currently are available on Hatch Ventures’ website, HatchVentures.com.
Amgen’s Xgeva receives FDA approval
SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for preventing skeletal injuries in patients whose cancer has spread to the bone.
The FDA announced Friday the approval of Thousand Oaks, Calif.-based biotech company Amgen’s Xgeva (denosumab) for bone metastases.
The drug is a monoclonal antibody that targets RANKL, a protein involved in the destruction of bones in patients with cancer. Other treatments for similar conditions include Novartis’ drugs Zometa (zoledronic acid) and Aredia (pamidronate disodium).
“Bone metastases represent a major cause of pain and suffering in patients with cancer and can affect a patient’s quality of life,” FDA Office of Oncology Drug Products director Richard Pazdur said. “Xgeva has a different mechanism of action than currently approved drugs aimed at reducing bone complications from cancer.”